Pharmaceuticals DC $500K+ Reviewed

2-PAM Autoinjectors Project Bioshield

HHS

Washington, DC

nerve agent antidotes pralidoxime autoinjectors chemical countermeasures $500K+

Posted Jun 2, 2026

Due Jun 16, 2026

Description

The U.S. Department of Health and Human Services is procuring 2-PAM (pralidoxime chloride) autoinjectors under Project Bioshield to stockpile medical countermeasures against nerve-agent and organophosphate exposure. The solicitation focuses on acquiring FDA-approved autoinjector products suitable for rapid field administration in public health emergencies. Pharmaceutical companies with experience in antidote manufacturing, autoinjector technology, and BARDA or SNS contracts are the most likely bidders.

A strong match for healthcare vendors

Curated for medical & healthcare suppliers

Why we classified this as medical

Title explicitly names 2-PAM (pralidoxime) autoinjectors under Project Bioshield, a program for medical countermeasures against chemical threats; this is procurement of pharmaceutical-filled autoinjector devices for clinical antidote use.

View Original Source

Save for Later

Send to Pipeline